Our Unique Approach Makes the Oncology Therapeutic Area Our Specialty

Did you know that only 5 percent of oncology drugs are approved by the FDA? Are you aware that 70 percent of oncology studies are cancelled in Phase II?

Judging by those statistics, you certainly need a team of study delivery experts on your side to give your oncology trial the best chance for success. Here at Datatrial, one-third of the studies we’ve conducted have been in the oncology therapeutic area. Armed with that extensive background and a customized, flexible approach to study delivery, we’re an oncology CRO that is uniquely positioned to conduct your oncology trial with maximum efficiency—and a minimum of stress.

Our Oncology CRO Team is Experienced in Handling the Unique Variables Inherent to this Area

Our nowEDC™ software gives us the flexibility needed to accommodate all the variables of your oncology study, while reducing the costs involved with printing and distributing voluminous amounts of CRF pages. We can also perform selective assessments on different treatment arms in order to collect pertinent data—all while maintaining research validity, integrity and efficiency.

The oncology therapeutic area deals with complex medications and, often, extremely sick patients. As a result, the number of adverse events can be dramatically higher than early-phase studies in other therapeutic areas. As an oncology CRO, not only do we recognize the need for a dynamic system that can handle these unique needs, but we’re also cognizant of the special care called for under these circumstances.

If you would like to learn more about how we conduct studies in the oncology therapeutic area, contact us to chat with one of our study delivery experts. You can also check out our new article detailing our unique approach to early-phase oncology studies or view our case studies to see how we’ve helped companies like Nexus Oncology  achieve success as their oncology CRO partner.